Millennium Management
ENSC icon

Millennium Management’s Ensysce Biosciences ENSC Stock Holding History

Millennium Management’s Portfolio ENSC Stock Details ENSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-80
Closed -$11K – 6481
2022
Q4 		$11K Buy
+80
New +$38K ﹤0.01% 6170
2021
Q4 		– Sell
-11
Closed -$115K – 6937
2021
Q3 		$115K Buy
+11
New +$215K ﹤0.01% 6375

Other funds holding ENSC

VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
PIA
Powell Investment Advisors Miami, Florida $290M AUM 21.61% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
ASN
Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return
PMFA
Plante Moran Financial Advisors Southfield, Michigan $1.55B AUM 17.93% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Millennium Management's ENSC Position: Q1 2023 in Review

Millennium Management sold out of Ensysce Biosciences (ENSC) in Q1 2023, closing a stake of 80 shares — an estimated $11K sold.

Millennium Management first reported a position in ENSC in Q3 2021 and held it in 2 quarters. The position peaked at $115K in Q3 2021. 8 funds tracked by Wall St. Rank hold ENSC as of Q1 2023.

  • Millennium Management reported no remaining Ensysce Biosciences position as of Q1 2023 after selling out during the quarter.
  • Millennium Management sold 80 Ensysce Biosciences shares in Q1 2023, an estimated $11K.
  • Millennium Management first reported a position in Ensysce Biosciences in Q3 2021 and held it in 2 quarters.
  • Millennium Management's Ensysce Biosciences position peaked at $115K in Q3 2021.
  • 8 funds tracked by Wall St. Rank held Ensysce Biosciences as of Q1 2023.

Based on Millennium Management's 13F filing for Q1 2023, filed 15 May 2023.